Testing a new antibody combined with an existing drug for lymphoma resistant to prior treatment

This trial is testing whether a new antibody medication called MIL62, when combined with lenalidomide, works better than lenalidomide alone for people with follicular lymphoma—a type of blood cancer—that has not responded to a common prior treatment. About 168 people will be randomly assigned to receive either the new medication plus lenalidomide or lenalidomide by itself. The study will measure whether the combination helps control the cancer better and is safe to take.

Some people with follicular lymphoma do not respond well to the standard first-line treatment, leaving them with limited options. Researchers believe that adding this new antibody medication to an existing drug might help people whose cancer has already resisted prior therapy.